Literature DB >> 22203760

Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

Vivek Subbiah1, John Slopis, David S Hong, Leena M Ketonen, Jackson Hamilton, Ian E McCutcheon, Razelle Kurzrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22203760      PMCID： PMC3295556          DOI： 10.1200/JCO.2011.38.2614

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

Review 1.  Targeted drug therapy for meningiomas.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Neurosurg Focus       Date:  2007       Impact factor: 4.047

Review 2.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

3.  Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.

Authors:  Scott R Plotkin; Chris Halpin; Michael J McKenna; Jay S Loeffler; Tracy T Batchelor; Fred G Barker
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

4.  Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.

Authors:  Victor-Felix Mautner; Rosa Nguyen; Hannes Kutta; Carsten Fuensterer; Carsten Bokemeyer; Christian Hagel; Reinhard E Friedrich; Jens Panse
Journal:  Neuro Oncol       Date:  2009-10-20       Impact factor: 12.300

5.  Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Authors:  Scott R Plotkin; Marybeth A Singh; Caroline C O'Donnell; Gordon J Harris; Andrea I McClatchey; Chris Halpin
Journal:  Nat Clin Pract Oncol       Date:  2008-06-17

Review 6.  Neurofibromatosis 2.

Authors:  Michael E Baser; D Gareth R Evans; David H Gutmann
Journal:  Curr Opin Neurol       Date:  2003-02       Impact factor: 5.710

7.  Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.

Authors:  Apostolia Maria Tsimberidou; Michelle A Rudek; David Hong; Chaan S Ng; Jessica Blair; Howard Goldsweig; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2010-01       Impact factor: 3.333

8.  Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.

Authors:  D Gareth Evans; Marco Giovannini; Michel Kalamarides; Kim Hunter-Schaedle; Jaishri Blakeley; Jeffrey Allen; Dusica Babovic-Vuskanovic; Allan Belzberg; Gideon Bollag; Ruihong Chen; Emmanuelle DiTomaso; John Golfinos; Gordon Harris; Abraham Jacob; Ganjam Kalpana; Matthias Karajannis; Bruce Korf; Razelle Kurzrock; Meng Law; Andrea McClatchey; Roger Packer; Pamela Roehm; Allan Rubenstein; William Slattery; James H Tonsgard; D Bradley Welling; Brigitte Widemann; Kaleb Yohay
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

Review 9.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

Review 10.  The neurofibromatoses. Part 2: NF2 and schwannomatosis.

Authors:  Christine Lu-Emerson; Scott R Plotkin
Journal:  Rev Neurol Dis       Date:  2009
View more
  17 in total

1.  Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.

Authors:  S Moulder; T Helgason; F Janku; J Wheler; J Moroney; D Booser; C Albarracin; P K Morrow; J Atkins; K Koenig; M Gilcrease; R Kurzrock
Journal:  Ann Oncol       Date:  2015-04-15       Impact factor: 32.976

Review 2.  Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors:  Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-17       Impact factor: 5.081

3.  Essential signaling in NF2 loss-related tumours: the therapeutic potential of CRL4DCAF1 and mTOR combined inhibition.

Authors:  Helena J Janse van Rensburg; Xiaolong Yang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 4.  Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.

Authors:  Jaishri Blakeley
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2012-10       Impact factor: 2.064

5.  Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.

Authors:  Audrey Hochart; Vianney Gaillard; Marc Baroncini; Nicolas André; Jean-Pierre Vannier; Matthieu Vinchon; Frederique Dubrulle; Jean-Paul Lejeune; Christophe Vincent; Véronique Nève; Héléne Sudour Bonnange; Nicolas Xavier Bonne; Pierre Leblond
Journal:  J Neurooncol       Date:  2015-05-29       Impact factor: 4.130

6.  Ewing's sarcoma: overcoming the therapeutic plateau.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Discov Med       Date:  2012-06       Impact factor: 2.970

Review 7.  The role of stem cells in benign tumors.

Authors:  Haiyan Qin; Dongyu Bao; Xin Tong; Qingang Hu; Guowen Sun; Xiaofeng Huang
Journal:  Tumour Biol       Date:  2016-09-21

8.  Inhibition of c-Jun N-terminal kinase activity enhances vestibular schwannoma cell sensitivity to gamma irradiation.

Authors:  Wei Ying Yue; J Jason Clark; Michael Telisak; Marlan R Hansen
Journal:  Neurosurgery       Date:  2013-09       Impact factor: 4.654

Review 9.  NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.

Authors:  Rebecca Dunbar Schroeder; Laura S Angelo; Razelle Kurzrock
Journal:  Oncotarget       Date:  2014-01-15

Review 10.  Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.

Authors:  Ryota Tamura
Journal:  Int J Mol Sci       Date:  2021-05-29       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.